Floatz logo

Daunorubicin

Lymphoblastic Lymphoma

City of Hope Medical CenterPhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
73/ 100

Competitive context

83 Active assets in the Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 4BBB
PEGASPARGASE
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 4BBB
VINDESINE
University Hospital Muenster
Phase 4BBB
MERCAPTOPURINE ANHYDROUS
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →